| 张旭艳,毛 红,杨 帆,李 丽,蒋小婉.利拉鲁肽联合利格列汀治疗2型糖尿病肥胖患者的临床研究[J].,2019,19(15):2895-2899 |
| 利拉鲁肽联合利格列汀治疗2型糖尿病肥胖患者的临床研究 |
| Clinical Observation of Liraglutide Combined with Linagliptin in Treatment of Obesity Patients with Type 2 Diabetes Mellitus |
| 投稿时间：2019-02-05 修订日期：2019-02-28 |
| DOI：10.13241/j.cnki.pmb.2019.15.021 |
| 中文关键词: 2型糖尿病 肥胖 利拉鲁肽 利格列汀 疗效 |
| 英文关键词: Type 2 diabetes mellitus Obesity Liraglutide Linagliptin Efficacy |
| 基金项目:湖北省卫生和计划生育委员会科研项目（WJ2017M183） |
|
| 摘要点击次数: 645 |
| 全文下载次数: 546 |
| 中文摘要: |
| 摘要 目的：探讨利拉鲁肽联合利格列汀治疗2型糖尿病肥胖患者的临床疗效。方法：选取2016年1月至2018年1月本院收治的104例2型糖尿病肥胖患者，按照随机数字表法将患者分为对照组（n=52）和治疗组（n=52）。对照组给予利格列汀治疗，治疗组给予利拉鲁肽联合利格列汀治疗，两组疗程均为3个月。比较两组治疗前后体质量指数（BMI）、血糖指标[糖化血红蛋白（HbA1c）、空腹血糖（FPG）、餐后2小时血糖（2hPG）]、血压指标[收缩压（SBP）、舒张压（DBP）]、胰岛功能指标[胰岛素抵抗指数（HOMA-IR）、胰岛β细胞功能（HOMA-β）]、骨代谢指标[N端中段骨钙素（N-MID-OT）、β胶联降解产物（β-CTX）]、氧化应激指标[丙二醛（MDA）、脂质过氧化氢（LHP）、谷胱甘肽过氧化物酶（GSH-Px）]和炎症指标[肿瘤坏死因子-α（TNF-α）、白细胞介素-6（IL-6）、C反应蛋白（CRP）]水平，记录两组治疗过程中不良反应的发生情况。结果：治疗后，两组的BMI、血糖指标、血压指标、HOMA-IR、β-CTX、MDA、LHP、炎症指标水平均低于治疗前，HOMA-β、N-MID-OT、GSH-Px水平均高于治疗前（P<0.05），且治疗组以上指标的改善程度明显优于对照组。治疗组不良反应发生率为15.38%（8/52），与对照组的11.54%（6/52）比较差异无统计学意义（P>0.05）。结论：利拉鲁肽联合利格列汀治疗2型糖尿病肥胖患者安全有效，能够明显降低患者体重、血糖、血压水平，改善胰岛功能和骨代谢，减轻氧化应激和炎症反应。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the clinical efficacy of liraglutide combined with linagliptin in treatment of obesity patients with type 2 diabetes mellitus. Methods: 104 obesity patients with type 2 diabetes mellitus who were treated in our hospital from January 2016 to January 2018 were selected. The patients were divided into control group (n=52) and treatment group (n=52) according to random number table. The control group were given linagliptin, and the treatment group was treated with liraglutide combined with linagliptin, the course of treatment was 3 months in the two groups. The body mass index (BMI), blood glucose indexes [fasting plasma glucose (FPG), 2 hour postprandial blood glucose (2hPG), glycated hemoglobin (HbA1c)], blood pressure indexes [systolic blood pressure (SBP), diastolic blood pressure (DBP)], islet function index [(HOMA-IR), islet β cell function (HOMA-β)] and bone metabolism indexes [N-MID-OT, β-CTX], oxidative stress indexes [malondialdehyde (MDA), lipid peroxide (LHP), glutathione peroxidase (GSH-Px)] and inflammatory indexes [tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), C-reactive protein (CRP) ] levels were compared between the two groups before and after treatment. The occurrence of adverse reactions in the two groups were recorded. Results: The BMI, blood glucose indexes, blood pressure indexes, HOMA-IR, β-CTX, MDA, LHP and inflammatory indexes after treatment were lower than those before treatment in both groups. The levels of HOMA-β, N-MID-OT and GSH-Px were all higher than those before treatment(P<0.05). And the improvement of the above indexes in the treatment group was obviously better than that in the control group. The incidence of adverse reactions in the treatment group was 15.38% (8/52), there was no significant difference of 11.54% (6/52) in the control group(P>0.05). Conclusion: Liraglutide combined with linagliptin in treatment of obesity patients with type 2 diabetes mellitus is efficacy and safety, it can reduce the body weight, blood glucose, blood pressure levels of patients, and it can improve the islet function and bone metabolism, reduce oxidative stress and inflammation response. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
